UNSPSC 51432803: Enalapril

This classification denotes an ace inhibitor with the molecular formula C20H28N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69PN84IO1A, chemically known as l-proline, n-((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl- but generally known as enalapril, which bears US NIH Compound Identifier 5362032. European Medicines Agency schedules Enalapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06514MIG. The term ENALAPRIL is an International Non-Proprietary Name.

UNSPSC 51432803 Enalapril, a Commodity code, classifies pharmaceutical products for state and local government procurement. State and local buying under this code centers on emergency medications and multi-source generic pharmaceuticals for public health agencies, fire departments, and health-plan administration. Recent solicitations show purchasing of individual Advanced Life Support medications (including enalapril-class agents) for emergency medical services, as well as broader framework agreements for generic multi-source drugs distributed across state and local facilities. Issuing bodies span municipal fire departments and emergency services, state health agencies, and cooperative purchasing alliances administered at the state level that serve multiple jurisdictions. The City of Tampa's Purchasing Department and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, are the repeat buyers evident in recent activity. Vendors must meet FDA compliance, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, OSHA Hazard Communication Standards documentation, and expiration-date requirements (typically nine months to one year from delivery or manufacture).

Activity clusters in Florida and the Upper Midwest, with the Texas Health and Human Services Commission also conducting early-stage market research. Representative recent opportunities include the City of Tampa's sealed-bid solicitation (No. 26P00188) for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000.00 and a Small Local Business Enterprise (SLBE) sheltered-market designation offering a 5 percent bid discount; the Minnesota MMCAP Request for Proposal (No. S1070000015802) for generic multi-source pharmaceuticals and OTC products with a proposal due date of March 26, 2026, establishing multiple contracts effective July 1, 2026 across Minnesota, Oregon, and participating jurisdictions; and the Texas HHS Commission's Request for Information (No. HHS0017013) issued April 3, 2026, exploring direct-to-manufacturer prescription programs for future formal solicitation. Cooperative purchasing vehicles and state-managed alliances dominate the broader multi-source opportunity landscape, while municipal emergency services generate smaller, more frequent individual-medication procurement cycles.